Challenge epilepsy: new antiepileptic drugs
Challenge of Epilepsy provides a short summary of the actual status of development, testing, and application of new Antiepileptic Drugs (AEDs). Special emphasis is laid on critical evaluation of methodical approaches, and to the actual clinical experiences with new AEDs. A new approach is successfully applied: interdisciplinary work on the basic research, clinical research, as well as application for admission at the respective institutions.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Perspectives of new antiepileptic drugs in psychiatric disorders
therapeutic aspects in the elderly
lndications for new antiepileptic drugs
6 other sections not shown
active control add-on therapy animal models anticonvulsant anticonvulsant activity anticonvulsant drugs antiepileptic drugs c-Fos carbamazepine Clin Pharmacol clinical trials clobazam cognitive effects cognitive side-effects compared compound controlled trial cytochrome deutschmarks disease management dosage dose double-blind drug interactions DULAC efficacy elderly Epilepsia 36 suppl epilepsy Epilepsy Res equivalence trials ethosuximide evaluation felbamate GABA gabapentin half-life healthy volunteers hippocampal impairment increase induced infantile spasms inhibition lamotrigine Lennox-Gastaut syndrome LEPPlK lnternational long-term Losigamone mechanism of action metabolism metabolite monotherapy Neurol Neurology newly diagnosed OCBZ oral outcome oxcarbazepine partial epilepsy partial seizures Perucca pharmaco-economics pharmacokinetics pharmacology phenobarbital phenytoin placebo placebo-controlled plasma polytherapy potential protein binding R.H. Mattson rats Raven Press receptor Remacemide renal SACHDEO seizure free seizure models serum levels sodium valproate stiripentol syndrome therapeutic threshold tiagabine tion tolerability topiramate toxicity treatment valproic acid vigabatrin zonisamide